Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Albany Molecular Research Inc Issues FY 2013 EPS Guidance Above Analysts' Estimates
Albany Molecular Research Inc announced that for fiscal 2013, it expects adjusted earnings per share range of $0.34 to $0.52. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $0.24 for fiscal 2013.
Latest Developments for Albany Molecular Research Inc
- Albany Molecular Research Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance; Issues Q2 2013 Guidance
- Albany Molecular Research Inc Issues Q4 2012 EPS Guidance Above Analysts' Estimates; Raises FY 2012 EPS Guidance
- Albany Molecular Research, Inc. Issues Q3 2012 EPS Guidance In Line With Analysts' Estimates; Raises FY 2012 EPS Guidance
- Albany Molecular Research, Inc. Issues FY 2012 EPS Guidance-Conference Call
Latest Key Developments in Biotechnology
- Rockwell Medical Inc Closes $40.3 Million Public Offering Of Common Stock
- Rockwell Medical Inc Announces PRIME Study Results At The 50th ERA-EDTA Meeting In Istanbul
- Intercept Pharmaceuticals Inc Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
- Synageva BioPharma Corp's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from U.S. Food and Drug Administration
- Share this
- Link this
- Digg this
Follow Reuters